PACB Pacific Biosciences of California Inc

$PACB After nearly 30 years of investing, I will never be able to understand how the scumbags behind the curtain can hold down a stock for 2.5 years and then that stock doubles in less than a month out of nowhere.

$PACB here for the long haul, everything in between is noise, people “hoping” a genome company crashes have no morals, data is being used to cure diseases and make life longer. Pathetic

$PACB The whole biotech-sector with significant downs/losses today: Illumina, Intellia, CRISPR, and even Moderna and so on. So "nothing special" here.Thats the stock market and belongs to the "game". By the way: For the massive gains the last days is PACBs price until this moment absolutely tolerable to my opinion. Did not sell even one share. (Bought my first position of CRISPR today at 54.45.)

$PACB stocks are never rational. You might doubt about the strong soar but remember it should not have been that low at all to begin with.

$PACB Started a short near $2.6 and will add more if higher on the fluff pump (future dreams and rainbows). Huge bubble to swiftly plummet at the Q3 financial report: -Revenue guidance has been drastically reduced. Growth rate is zero, competition is ruthless, and adoption in the ditch. -Net loss of -45M per quarter = will never ever be profitable. -Cash burn of -40M every single quarter = cash evaporates in 2027. -Hefty debt of 650M to be refinanced at much higher rates = risk of BK. -Hefty dilution every single quarter of the outstanding shares. -No prestigious bio funds are invested. -High short interest = consensus of poor stock. -Last analyst has price target of $1.35.

$PACB we turned down a buyout from $ILMN a few years back valued at 1.2ish billion. Keep in mind that was pre-AI speeding up sequencing rate, pre-basecamp with $NVDA and much more than our current market cap, I’m sitting tight

$PACB Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. Foot in the door with the US Government, first hand look at how PacBio technology can help drill down into large population sets. This is a big deal beyond the higher throughput for the US’ largest Revio user.

$PACB PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

$PACB A psychoanalytic interpretation of today's stock performance: Over 11 million shares traded so far, and the stock is clearly in the green. This means the market has not only confirmed last week's rise but has also reinforced it. Absolutely bullish.

$PACB Volume today. 35,823,132. Closed in deep green after 30% plus yesterday. Wow: That's a statement! from the market.

$PACB Volume is only 62M shares for the day. There is no way shorts could cover 52M shares short today. Sans news, squeeze should continue tomorrow; with positive news, shorts will get crushed....

$PACB Building on years of work supporting the MVP, Sampled has provided array genotyping, long-read whole genome sequencing, DNA methylation analysis, and proteomics assays for the program. Equipped with multiple PacBio Revio long-read sequencing systems, Sampled is uniquely positioned to deliver robust and high-throughput long-read sequencing workflows and is among the largest users of the Revio platform in the US.

$PACB yesterday's breakout above $2.75 (a feat that PABB had been unable to perform in the last 30 months) should act as excellent support going forward.

$PACB Revio showed the lowest pull through estimates last quarter, $202,000 annuallly. Pull through (companies using their Revios and buying consumables) peaked at around $242,000 in recent years. The government contract is going to increase pull through and possibly lead to additional Revio acquisitions to support the project. While it may be a couple of quarters away, once the Million Veteran Program commences, the Revios are going to be running and consuming.

$PACB the last two minutes of trading we traded from a low of $2.61 to close at $2.72 on 4 million shares. Something big is brewing. Look for a close over $3 by end of day Friday.

$PACB closed today at a 30 month high on 3x's the average daily volume. Massive triple top above $2.75 has my first target at $5 and with a trade of $3 we're headed to $6

$PACB Lots of recent hit pieces on Pac Bio by low level penny stock outlets. Yet volume remains strong and gains remain constant despite the overall market dropping. These look like hit pieces to Razor to get weak hands to sell that's for sure.

$PACB I am holding strong on my short, until they release they usual lame financials with no growth and big losses. The market will also hate their deteriorating balance sheet. That is why insiders sold a huge amount to retail.

$PACB — This new AI partnership adds another use case for long-read sequencing. PacBio announced a collaboration with TychoBio to generate full-length RNA data from more than 10,000 samples. TychoBio plans to use the sequencing information to train AI models for designing RNA-based therapies targeting rare diseases. This is interesting because the value of sequencing technology could extend beyond diagnostics and basic research into drug development. However, PacBio recently lowered its full-year revenue forecast, so commercial execution remains a legitimate concern.

$PACB Razor thinks a lot of esse's are not only covering, but exiting their positions in and and going long in